DSL(SH:603233) Shang Hai Zheng Quan Bao·2025-10-09 19:02Core Viewpoint - The announcement details the conversion results of the convertible bonds issued by Dazhenlin Pharmaceutical Group Co., Ltd., indicating minimal conversion activity and a significant amount of unconverted bonds as of September 30, 2025 [2][10]. Convertible Bond Issuance Overview - Dazhenlin Pharmaceutical issued 14,050,000 convertible bonds with a total value of RMB 1,405 million, which began trading on November 13, 2020 [4]. - The bonds have a face value of RMB 100 each and were approved by the China Securities Regulatory Commission [4]. Conversion Details - As of September 30, 2025, a total of RMB 362,000 of "Dazhen Convertible Bonds" has been converted into company shares, representing 0.0258% of the total issuance [2][10]. - The total number of shares converted is 6,242, which accounts for 0.0009% of the company's total shares before the conversion [2][10]. - No new conversions occurred in the third quarter of 2025 [3][10]. Unconverted Bonds - As of September 30, 2025, the amount of unconverted convertible bonds stands at RMB 1,404,638,000, which is 99.9742% of the total issuance [2][11]. Conversion Price Adjustments - The conversion price of the bonds has undergone several adjustments due to corporate actions, with the latest adjustment setting the price at RMB 17.69 per share as of May 20, 2025 [9].